- Investing.com
Pipeline Promise | Relay Therapeutics advances RLY-2608 for breast cancer, with potential $4B market. Three new programs set to enter clinical stages in 2025, expanding therapeutic reach. |
Competitive Edge | Despite fierce competition, Relay maintains first-mover advantage in PI3K inhibitors. Pfizer collaboration strengthens position in HR+/HER2- breast cancer treatment. |
Financial Outlook | Cash runway extends to 2026, but operating losses persist. Analysts set average price target at $16.33, ranging from $14 to $21, reflecting mixed market sentiment. |
Risk vs. Reward | Q4 2024 data readout crucial for RLY-2608. Success could boost stock and attract investors, while setbacks may impact pipeline and market position significantly. |
Chỉ số cần so sánh | RLAY | Lĩnh vực Ngành- Số liệu trung bình từ một nhóm lớn các công ty Y Tế liên quan thuộc ngành | Mối quan hệ Mối quan hệRLAYCông TyLĩnh vực | |
---|---|---|---|---|
Tỉ số P/E | −1.9x | −0.5x | −0.6x | |
Tỷ Lệ PEG | −0.08 | −0.02 | 0.00 | |
Giá/G.Trị Sổ Sách | 0.9x | 2.5x | 2.6x | |
Giá / Doanh Số 12T | 71.0x | 7.1x | 3.3x | |
Tăng (Mục Tiêu của Nhà Phân Tích) | 297.1% | 277.8% | 39.5% | |
Giá Trị Hợp Lý Tăng | Mở Khóa | 10.4% | 4.9% | Mở Khóa |